Reducing bias in bacterial community analysis of lower respiratory infections by Rogers, Geraint B. et al.
 
Copyright © 2013 International Society for Microbial Ecology 
 
This version available http://nora.nerc.ac.uk/20879/  
 
 
NERC has developed NORA to enable users to access research outputs 
wholly or partially funded by NERC. Copyright and other rights for material 
on this site are retained by the rights owners. Users should read the terms 
and conditions of use of this material at 
http://nora.nerc.ac.uk/policies.html#access  
 
 
This document is the author’s final manuscript version of the journal 
article following the peer review process. Some differences between 
this and the publisher’s version may remain. You are advised to 
consult the publisher’s version if you wish to cite from this article. 
 
www.nature.com/  
   
 
 
Article (refereed) - postprint 
 
 
 
Rogers, Geraint B.; Cuthbertson, Leah; Hoffman, Lucas R.; Wing, Peter 
A.C.; Pope, Christopher; Hooftman, Danny A.P.; Lilley, Andrew K.; Oliver, 
Anna; Carroll, Mary P.; Bruce , Kenneth D.; van der Gast, Christopher J.. 
2013 Reducing bias in bacterial community analysis of lower respiratory 
infections. ISME Journal, 7 (4). 10.1038/ismej.2012.145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contact CEH NORA team at  
noraceh@ceh.ac.uk 
 
 
The NERC and CEH  trademarks and logos (‘the Trademarks’) are registered trademarks of NERC in the UK and 
other countries, and may not be used without the prior written consent of the Trademark owner. 
1 
 
Towards unbiased bacterial community analysis in lower respiratory infections 1 
 2 
Geraint B. Rogers
1
,
 
Leah Cuthbertson
2
, Lucas R. Hoffman
3
, Peter A. C. Wing
4
, Christopher Pope
3
, Danny A. 3 
P. Hooftman
2
, Andrew K. Lilley
1
, Anna Oliver
2
, Mary P. Carroll
4
, Kenneth D. Bruce
1
, Christopher J. van der 4 
Gast
2*
 5 
 6 
1
Institute of Pharmaceutical Science, Molecular Microbiology Research Laboratory, King's College London, 7 
London, SE1 9NH, UK 8 
2
NERC Centre for Ecology and Hydrology, Wallingford, OX10 8BB, UK 9 
3
Departments of Pediatrics and Microbiology, University of Washington, Box 356320, HSB K328A, Seattle, 10 
WA 98105, USA 11 
4
Cystic Fibrosis Unit, Southampton University Hospitals NHS Trust, Southampton, SO16 6YD, UK 12 
 13 
* For correspondence: E-mail cjvdg@ceh.ac.uk 14 
 15 
Running title: Impact of PMA on CF bacterial community analysis 16 
 17 
Subject category: Microbial population and community ecology 18 
 19 
The sequence data have been submitted to the Science Research Associates (SRA) database, hosted by 20 
the NCBI, under the study accession number SRA051980. 21 
 22 
Supplementary information: Figure S1; Tables S1, S2, and S3 23 
  24 
2 
 
Abstract 25 
High-throughput pyrosequencing and quantitative PCR analysis offer greatly improved accuracy and 26 
depth of characterisation of lower respiratory infections. However, such approaches suffer from an inability to 27 
distinguish between DNA derived from viable and non-viable bacteria. This discrimination represents an 28 
important step in characterising microbial communities, particularly in contexts with poor clearance of 29 
material or high antimicrobial stress, as non-viable bacteria and extracellular DNA can contribute significantly 30 
to analyses. Pre-treatment of samples with propidium monoazide (PMA) is an effective approach to non-31 
viable cell exclusion (NVCE). However, the impact of NVCE on microbial community characteristics 32 
(abundance, diversity, composition and structure) is not known. Here, we use adult cystic fibrosis (CF) 33 
sputum samples as a paradigm. The effects of PMA treatment on CF sputum bacterial community 34 
characteristics, as analysed by pyrosequencing and enumeration by species-specific (Pseudomonas 35 
aeruginosa) and total bacterial Q-PCR, were assessed. At the local community level, abundances of both 36 
total bacteria and of P. aeruginosa were significantly lower in PMA treated sample portions. Meta-analysis 37 
indicated no overall significant differences in diversity; however, PMA treatment resulted in a significant 38 
alteration in local community membership in all cases. In contrast, at the metacommunity level, PMA 39 
treatment resulted in an increase in community evenness, driven by an increase in diversity, predominately 40 
representing rare community members. Importantly, PMA treatment facilitated the detection of both 41 
recognised and emerging CF pathogens, significantly influencing ‘core’ and ‘satellite’ taxa group 42 
membership. Our findings suggest failure to implement NVCE may result in skewed bacterial community 43 
analyses. 44 
 45 
Keywords: propidium monoazide, pyrosequencing, 16S ribosomal RNA gene, metacommunity, quantitative 46 
PCR, cystic fibrosis, commonness and rarity 47 
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Introduction 49 
The first key step of analysing a microbial community is accurately defining the bacterial taxa 50 
present. From this, a range of ecological insights can follow in terms of understanding and predicting the 51 
impact and response of communities to perturbation. Such approaches have been of importance for some 52 
time when assessing the response(s) of communities present in natural environments (Ager et al 2010). 53 
More recently, awareness has grown of the benefit of applying these techniques to both normal and 54 
pathogenic bacterial communities associated with the human host. In humans, mixed species infections are 55 
commonplace (Brogden et al 2005); and, defining the roles played by bacteria in chronic lower respiratory 56 
infections is particularly important. Taking cystic fibrosis (CF) as a paradigm, the lung damage that results 57 
from such infections drives respiratory failure and death in the overwhelming majority of cases (Davis et al 58 
1996). Understanding the ecological patterns and processes may allow improvement in therapy. However, 59 
before being able to do so, it is important to determine accurately the community characteristics of CF 60 
airways. 61 
16S rRNA gene pyrosequencing and quantitative PCR analysis offer greatly improved accuracy and 62 
depth of characterisation of microbial communities.  However, whilst avoiding the selective biases associated 63 
with culture-based microbiology, culture-independent approaches will distort to some degree the 64 
characteristics of the systems they are being used to describe. For example, standard PCR-based analyses 65 
are unable to distinguish between DNA derived from viable and non-viable bacterial cells. In the context of 66 
CF lung infections, the combination of poor clearance of airway secretions (Döring and Gulbins 2009) and 67 
exposure of bacterial cells to a range of antimicrobial challenges, both in the form of host immune response 68 
(Elizur et al 2008) and antibiotic therapy (Ratjen 2001), results in substantial non-viable populations (Rogers 69 
et al 2005, Rogers et al 2008, Rogers et al 2010). As such, the potential contribution of DNA, either from the 70 
extracellular environment or from non-viable cells, to microbial community characterisation is considerable. 71 
Failing to limit analysis to DNA from viable bacteria could have a number of effects on community 72 
characterisation. These include overestimating viable bacterial density; distorting relative viable species 73 
abundance, and the masking of less abundant species by dominant species. Further, the impact on 74 
community dynamics from antibiotic treatment in this context is less likely to be observed when DNA from 75 
bacteria rendered non-viable is not prevented from contributing to molecular analysis. Pre-treatment of 76 
samples with propidium monoazide (PMA) is an effective approach to non-viable cell exclusion (NVCE) 77 
(Nocker and Camper 2006). In brief, PMA intercalates into double-stranded nucleic acids. On exposure to 78 
bright light, cross-linking occurs (Nocker and Camper 2006), preventing the DNA from acting as a PCR 79 
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template (Nocker and Camper 2006, Nocker et al 2007a, Nocker et al 2007b). Importantly though, PMA is 80 
highly membrane impermeant (Nocker and Camper 2006). This means that whilst PMA is readily able to 81 
penetrate dead bacterial cells whose structural integrity has been lost, PMA is excluded from viable cells 82 
(Nocker and Camper 2009). 83 
PMA treatment for this purpose has been shown to be effective in a range of contexts (Bae and 84 
Wuertz 2009, Kralik et al 2010, Nam et al 2011, Nocker et al 2007a, Taskin et al 2011) including the 85 
assessment of microbiota present in CF airways samples (Rogers et al 2008, Rogers et al 2010, Stressmann 86 
et al 2011). Further, this strategy has been used previously in conjunction with bacterial pyrosequencing in 87 
waste water treatment systems (Nocker et al 2010). Whilst the benefits of NVCE are leading to its increasing 88 
deployment, its impact on microbial community data has not previously been determined. 89 
In this study, we detailed the application of NVCE to profiling the bacterial communities present in 90 
spontaneously expectorated sputum samples collected from adult CF patients. The aim of this study was to 91 
determine the effects of PMA treatment on bacterial community characteristics (abundance, diversity, 92 
composition and structure), as analysed by 16S rRNA gene pyrosequencing, total bacterial Q-PCR 93 
enumeration, and species-specific Q-PCR enumeration of Pseudomonas aeruginosa, a clinically important 94 
pathogen in CF airways disease (Ballmann et al 1998, Kosorok et al 2001). Comparisons were made first 95 
between paired PMA treated and non-treated samples (i.e., the local community level), before focusing on 96 
core and satellite groups of bacterial taxa within the entire collection of PMA and non-PMA treated samples 97 
(i.e., the metacommunity).   98 
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Materials and methods 99 
Thirty spontaneously expectorated sputum samples were collected from adult CF patients attending 100 
the Adult CF Clinic at the Southampton General Hospital, with full ethical approval (Southampton and South 101 
West Hampshire Research Ethics Committee (06/Q1704/26)). All patients were judged to be clinically stable 102 
by treating physicians at the time of sampling. Sputum samples were collected in sterile containers, placed 103 
on ice, and transported to the microbiology laboratory within 60 min. Samples were then frozen and stored at 104 
-80°C prior to analysis. Each sample was mixed by pipetting and divided into two equal portions, one of 105 
which was treated with PMA prior to DNA extraction. 106 
 107 
PMA cross-linking 108 
PMA was dissolved in 20% dimethyl sulfoxide to create a stock concentration of 20 mmol/L with this 109 
added to samples to give a final concentration of 50 μmol/L. Following an incubation period of 30 min in the 110 
dark with occasional mixing, samples were light exposed using LED Active Blue equipment (IB - Applied 111 
Science, Barcelona, Spain). After photo-induced cross-linking, cells were transferred to 1.5 mL microfuge 112 
tubes and pelleted at 5000 × g for 5 min prior to DNA isolation. 113 
 114 
DNA extraction 115 
Nucleic acid extractions were performed on 100 μL portions of sputum. Guanidinium thiocyanate–116 
EDTA–sarkosyl (500 μL) and PBS (500 μL), pH 8.0, were added to samples. Cell disruption was achieved 117 
using a Fastprep-24 Instrument (MP Biomedicals Europe, Illkirch, France) 6.5 m/s, 60 s, followed by 118 
incubation at 90 °C for 1 min and −20 °C for 5 min. Cell debris was pelleted by centrifugation at 12 000 × g 119 
for 2 min at 4 °C. Supernatant was transferred to a fresh microfuge tube. NaCl (to a final concentration of 0.5 120 
mol/L) and polyethylene glycol (to a final concentration of 15%) were added and DNA was precipitated at 4 121 
°C for 30 min. DNA was pelleted by centrifugation at 12 000 × g for 2min at 4 °C and resuspended in 300 μL 122 
of sterile distilled water. Samples were heated at 90 °C for 30 s and vortexed. Phenol/chloroform (1:1) (300 123 
μL) was added, and samples were vortexed for 20 s before centrifugation at 12 000 × g at 4 °C for 3min. The 124 
upper phase was then transferred to a fresh microfuge tube. Total DNA was then precipitated by the addition 125 
of an equal volume of isopropanol, a 0.1-volume 10 mol/L ammonium acetate, and 1 μL of GenElute linear 126 
polyacrylamide (Sigma-Aldrich, Gillingham, UK) and incubated at −20 °C for 25 min. DNA was pelleted by 127 
centrifugation at 12 000 × g at 4 °C for 5 min. Pelleted DNA was then washed 3 times in 70% ethanol, dried, 128 
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and resuspended in 50 μL of sterile distilled water. DNA extracts were quantified using the Picodrop 129 
Microlitre Spectrophotometer (GRI, Braintree, UK). 130 
 131 
Quantitative PCR 132 
All quantitative (Q)PCR analyses were performed in triplicate. Total bacterial density was determined 133 
using a Taqman assay, in which a 466 bp fragment of the 16S ribosomal RNA gene was amplified, as 134 
described previously (Nadkarni et al 2002). P. aeruginosa density was determined using a Taqman assay 135 
which amplified a 65 bp fragment of the regA gene, as described previously (Rogers et al 2010, Shannon et 136 
al 2007). Details of the relevant primers and probes used are shown in Supplementary Table S1. 137 
 138 
Pyrosequencing 139 
Bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) was performed as described 140 
previously (using Gray28F 5'-TTTGATCNTGGCTCAG-3' and Gray519r 5'-GTNTTACNGCGGCKGCTG-3'). 141 
Initial generation of the sequencing library involved a one-step PCR of 30 cycles, using a mixture of Hot Start 142 
and HotStar high fidelity taq polymerase, as described previously (Dowd et al 2008). Tag-encoded FLX 143 
amplicon pyrosequencing analyses utilized Roche 454 FLX instrument with Titanium reagents, titanium 144 
procedures performed at the Research and Testing Laboratory (Lubbock, TX) using RTL protocols 145 
(www.researchandtesting.com).  146 
 147 
Sequence processing 148 
Following sequencing, all failed sequence reads, low quality sequence ends and tags and primers 149 
were removed. Sequences with ambiguous base calls, sequences with homopolymers > 6bp were removed. 150 
Further, any non-bacterial ribosome sequences and chimeras were removed using Black Box Chimera 151 
Check software (B2C2) (Gontcharova et al 2010) as has been described previously (Dowd et al 2008). To 152 
determine the identity of bacteria in the remaining sequences, sequences were de-noised, assembled into 153 
OTU clusters at 97% identity, and queried using a distributed .NEt algorithm that utilizes Blastn+ 154 
(KrakenBLAST www.krakenblast.com) against a database of high quality 16S bacterial sequences. Using a 155 
.NET and C# analysis pipeline the resulting BLASTn+ outputs were compiled and data reduction analysis 156 
performed as described previously (Dowd et al 2008). 157 
 158 
 159 
7 
 
Bacterial identification 160 
Based upon the above BLASTn+ derived sequence identity (percent of total length query sequence 161 
which aligns with a given database sequence) the bacteria were classified at the appropriate taxonomic 162 
levels based upon the following criteria. Sequences with identity scores, to known or well characterized 16S 163 
sequences, greater than 97% identity (<3% divergence) were resolved at the species level, between 95% 164 
and 97% at the genus level, between 90% and 95% at the family and between 85% and 90% at the order 165 
level , 80 and 85% at the class and 77% to 80% at phyla. After resolution based upon these parameters, the 166 
percentage of each bacterial identity was individually analyzed for each sample providing relative abundance 167 
information within and among the individual samples based upon relative numbers of reads within each 168 
(Dowd et al 2008). 169 
 170 
Statistical analyses 171 
To determine whether sample sizes were large enough to effectively assess the diversity of bacteria 172 
in each of the sputum samples taken, we used finite (without replacement) single sample rarefaction 173 
calculated using the Species Diversity and Richness package (version 4.1.2, Pisces Conservation, 174 
Lymington, UK). 175 
We used meta-analyses to summarize the effect sizes of all 30 samples using Hedges’ d (Borenstein 176 
et al 2009), treating the different samples as independent of each other and the two treatments (PMA and 177 
non-PMA) as separate groups within samples. Per sample, the effect size (i.e., standardized mean 178 
difference (δ)) among treatments was expressed as: 179 
 180 
   
           
  
        
          
 
       
 
 
 181 
In which X1 and X2 are the sample means in the two groups, n1 and n2 the sample sizes and S1 and S2 the 182 
standard deviations within groups. The Standard Error of Mean per sample (SEMδ) was expressed as: 183 
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Subsequently, we calculated the overall average effect size M, weighted by variance of sample i (Vi) and the 188 
Standard Error of Mean of M (SEMM) as: 189 
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 194 
Three complementary measurements of diversity were used to compare bacterial diversity between 195 
paired non-treated and PMA treated samples, as previously described (Edwards et al 2001).  The indices 196 
used were species richness (S*), Shannon-Wiener index (H’), and Simpson’s index (D).  Differences in S*, H’ 197 
and D (converted to the intuitive reciprocal form (1/D)) were computed using the re-sampling randomization 198 
method of Solow (1993). It is known that pair wise comparisons will be affected by large differences in 199 
sample size (N) (Gihring et al 2012).  Therefore, an Excel macro-program was written to apply Solow’s 200 
method to the pair wise comparison of each of the three parameters (S*, H’ and D) with a uniform sub-201 
sample size (n = 1637).  The re-sampling was repeated 1000 times and the mean similarity coefficients and 202 
standard deviation were taken. The value of n = 1637 was chosen to match to the smallest sample size. For 203 
metacommunity level analyses, the smallest sample size was chosen for each pair wise comparison.   204 
The community compositions from paired samples were compared pair wise using the Sørensen 205 
similarity coefficient calculated from the numbers of shared species. To overcome differences in sample size 206 
(Gihring et al 2012), the similarity coefficients were calculated using an Excel macro-program written to 207 
resample each sample species list with a uniform sub-sample size (n = 1637) and calculate the similarity 208 
coefficients (Solow 1993).  The re-sampling was repeated 1000 times and the mean similarity coefficients 209 
and standard deviation were taken.  For metacommunity level analyses, the smallest sample size was 210 
chosen for each pair wise comparison.    211 
Poisson distribution tests were carried out according to the method described by Krebs (1999) and 212 
applied as previously described (van der Gast et al 2011).  Regression analysis, coefficients of determination 213 
(r
2
), residuals and significance (P) were calculated using Minitab software (version 14.2, Minitab, University 214 
Park, PA, USA).  215 
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Results and discussion 216 
The effect of PMA treatment on abundance 217 
Q-PCR based enumeration using a conserved 16S rRNA gene primer pair and probe was performed 218 
on each of the thirty spontaneously expectorated sputum samples to determine the abundance of bacteria in 219 
paired PMA treated and non-treated sputum samples (Figure 1A). Mean bacterial abundance across non-220 
PMA samples was 9.05 x 10
8
 ± 1.06 x 10
9
 CFU ml
-1
 (standard deviation of the mean, n = 30), ranging 221 
between 3.27 x 10
6
 and 4.03 x 10
9
 CFU ml
-1
. In contrast, bacterial abundance across PMA treated samples 222 
was 8.91 x 10
7
 ± 1.79 x 10
8
 CFU ml
-1
 (n = 30), ranging between 1.22 x 10
5
 and 7.50 x 10
8
 CFU ml
-1
. Further, 223 
the abundance of only P. aeruginosa in paired samples was determined through Q-PCR using primers and a 224 
probe specific for P. aeruginosa Toxin A synthesis regulating gene, regA (Figure 1C). The mean abundance 225 
of P. aeruginosa in non-PMA samples was 1.57 x 10
8
 ± 1.82 x 10
8
 CFU ml
-1
 compared to 2.50 x 10
7
 ± 1.82 x 226 
10
7
 CFU ml
-1
 in the PMA treated samples, ranging from 4.47 x 10
3
 to 6.15 x 10
8
 and 1.64 x 10
2
 ± 1.49 x 10
8
 227 
CFU ml
-1
 for non-PMA and PMA treated samples, respectively. 228 
A growing number of studies have observed that bacterial communities are highly variable between 229 
CF patients (e.g. Harris et al 2007, Rogers et al 2005, van der Gast et al 2011). To cover the large variation 230 
among samples we used meta-analysis (Borenstein et al 2009) to integrate effect sizes among sputum 231 
samples, i.e., the difference between with and without prior PMA treatment.  Meta-analysis is a statistical 232 
synthesis of different individual studies, used in medicine to test among different clinical trials (Borenstein et 233 
al 2009) or in ecology among different experimental studies (Marvier et al 2007). Importantly, the number of 234 
replicates within individual studies and the variation among these replications are used as weighting of the 235 
means. Here, we translated this into using the replications within the same sample as a study and so all 236 
paired samples as independent studies, hence, providing us with a powerful tool to study between sample 237 
effects rather than simply comparing means of individual samples by, for example, paired t-tests. 238 
Using the meta-analysis approach to assess the effects of PMA treatment on total bacterial 239 
abundance and P. aeruginosa abundance demonstrated significant and strong negative effects on 240 
abundance for all paired samples (Figure 1B&D).  Furthermore, the overall effect of PMA treatment 241 
demonstrated a significant reduction in abundance (Figure 3).  This would indicate that only DNA from extant 242 
viable cells was included in the analyses, excluding extracellular DNA and DNA from dead or damaged cells 243 
that would otherwise be incorporated into abundance measures using Q-PCR without prior PMA treatment.  244 
 245 
 246 
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The effects of PMA treatment on diversity and composition in local communities 247 
Targeted 454 high-throughput pyrosequencing was used to assess the diversity and composition of 248 
bacterial communities within each of the treated and non-treated paired samples. A total of 386213 bacterial 249 
sequence reads (mean = 6436.9 ± 634.2 (n = 60)) identifying 154 genera and 267 taxa, were generated from 250 
all of the sputum samples combined (Supplementary Tables S2 and S3). Rarefaction curves were used to 251 
test whether sample sizes per sample were sufficiently large to compare enough of the bacterial diversity 252 
(Supplementary Figure S1); this analysis indicated that richness values for the bacterial taxa sampled from 253 
all local communities became asymptotic or were approaching asymptotic status, providing stable estimates 254 
of diversity. In this way, confirmation that sufficiently large samples had been collected and bacterial diversity 255 
was not under-sampled was obtained. 256 
To avoid potential biases in comparisons of diversity between local communities due to varying 257 
number of sequences per sample (Gihring et al 2012), a randomised re-sampling method (with a uniform 258 
sub-sample size of n = 1637) using three indices of diversity (taxa richness (S*), Shannon-Wiener index (H’), 259 
and Simpson’s reciprocal index (1/D)) was employed (Supplementary Table S2). For brevity, the effects of 260 
PMA treatment on taxa richness are presented in Figure 2A, and the overall effects of PMA treatment on 261 
diversity (S*, H’ and 1/D) are given in Figure 3.  Richness across individual samples regardless of treatment 262 
was highly variable, with mean values of 21.0 ± 15.1 and 18.8 ± 15.3, respectively.  Meta-analysis of 263 
individual samples revealed both significant negative and positive effects on richness by PMA treatment 264 
(Figure 2B).  Although there was no overall significant effect on richness, and hence diversity (confirmed 265 
using H’ and 1/D measures of diversity (Figure 3)), the data here indicate that diversity can be either under- 266 
or over-estimated in local communities without prior PMA treatment. 267 
Changes in community composition due to PMA treatment were also investigated. The Sørensen 268 
index of similarity with a randomised re-sampling method (uniform sub-sample size of n = 1637) revealed a 269 
mean change in similarity of 0.46 ± 0.23 in PMA treated samples when compared to paired non-PMA treated 270 
samples (Figure 2C). Meta-analysis showed significant negative effects (decreases in similarity) for all 271 
individual paired samples (Figure 2D); with an overall significant negative effect on community composition 272 
(Figure 3).  Therefore, we propose that skewed observations of local community composition are reached 273 
without prior PMA treatment. 274 
 275 
 276 
 277 
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The effects of PMA treatment at the metacommunity level 278 
At the metacommunity level, it has been established that a dichotomy exists within metacommunity 279 
species abundance distributions (SADs), consisting of ‘regionally’ common and locally abundant core 280 
species and infrequent rare satellite species groups (e.g. Dolan et al 2009, Magurran and Henderson 2003, 281 
Ulrich and Zalewski 2006, Unterseher et al 2011).  Recently, we established that the core-satellite group 282 
approach can be applied to CF bacterial communities and that partitioning the two groups from a 283 
metacommunity revealed important aspects of SADs, which would otherwise be neglected without such a 284 
distinction (van der Gast et al 2011). 285 
In the current study, we employed the same approach to focus on PMA treatment effects at the 286 
metacommunity level.  To establish that the defined metacommunity, comprised of either the 30 PMA- or 287 
non-treated local communities, was coherent we first plotted the relationship between mean abundance of 288 
taxa and local community occupancy / persistence (Figure 4A&B).  The expectation for a coherent 289 
metacommunity would be a ‘regional’ community comprised of trophically similar individuals and species 290 
each of which is perceived to exist in a series of local communities from similar habitats linked by rationale 291 
dispersal of potentially interacting species between or into those local communities (i.e. by dispersal from 292 
outside of the metacommunity) (Prosser et al 2007), resulting in a positive relationship between distribution 293 
among sites and abundance.  Here we observed significant distribution-abundance relationships for both the 294 
PMA and non-PMA treated metacommunity (Figure 4A&B).  Therefore, as observed previously, the 295 
commonness and rarity of bacterial taxa in the treated or non-treated metacommunity was found to be 296 
related to their permanence (local communities occupied) (Hanski 1982, Magurran and Henderson 2003, 297 
van der Gast et al 2011).   298 
Next we objectively divided the treated and non-treated metacommunity SADs into core and satellite 299 
groups by decomposing the overall distribution using the ratio of variance to the mean abundance for each 300 
bacterial taxon (van der Gast et al 2011). The variance to mean ratio, or index of dispersion, is an index used 301 
to model whether species follow a Poisson distribution, falling between 2.5 and 97.5 % confidence limits of 302 
the χ
2
 distribution (Krebs 1999). Plotting the indices of dispersion against persistence throughout the 30 303 
samples without prior PMA treatment, 32 bacterial taxa were randomly distributed through space (i.e., those 304 
taxa that fall below the 2.5 % confidence limit line in Figure 4C).  Bacterial taxa that occurred only in a single 305 
sputum sample were excluded from this analysis, as their dispersion in space would have no variance.  306 
However, those 49 taxa were classified into the satellite group (81 taxa in total) and the remaining 68 non-307 
randomly distributed taxa classified as core group taxa, in the non-PMA treated metacommunity (see 308 
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Supplementary Table S3 for core and satellite identification).  For the PMA treated metacommunity, the 309 
satellite group was comprised of 163 taxa (with 112 taxa each occurring in only one sample) and 70 core 310 
group taxa (Figure 4D). 311 
Following the categorisation of the CF bacterial taxa into the two groups, the metacommunity SADs 312 
with and without prior treatment were visualised as rank-abundance plots to examine differences in diversity 313 
and metacommunity structure (Figure 5).  The slope values for each plot were used as a descriptive statistic 314 
of evenness, where a value of zero represents perfect evenness (Ager et al 2010).  A change in community 315 
structure was observed in the PMA treated metacommunity (b = -0.0137) when compared to the non-treated 316 
metacommunity (b = -0.0244).  Using the t-distribution test (Fowler et al 1998) allowed us to determine that 317 
the slopes were significantly different (t = 12.86; d.f. = 1,378; P < 0.0001); indicating an increase in 318 
community structure evenness following PMA treatment.  Furthermore, the changes in evenness were driven 319 
by changes in richness, where 149 taxa were observed in the non-PMA treated metacommunity compared to 320 
233 taxa in the PMA treated metacommunity (Figure 5).  We also determined whether previously undetected 321 
extant taxa, without prior PMA treatment, were either core (regionally common and locally abundant) or 322 
satellite (infrequent and rare) members of the metacommunity.  A total of 118 taxa were previously 323 
undetected, of which 106 were categorised as satellite group members and 12 taxa as core group members.  324 
Furthermore, a total of 34 taxa comprised of 31 satellite group and only 3 core group members, were not 325 
detected after prior PMA treatment.  Despite the inclusion of a small number of core taxa group members, 326 
we could conclude that the majority of taxa, both newly detected and undetected after PMA treatment, were 327 
predominately infrequent rare members of the metacommunity. 328 
Subsequently, we examined to what extent this drove overall patterns of diversity and composition of 329 
the metacommunity, by comparing mean richness and changes in composition for the whole 330 
metacommunity, and the core and satellite groups between treatments (Figure 6A).  Again to avoid potential 331 
biases in comparisons of diversity and composition between samples due to varying mean numbers of 332 
sequences, we used a randomised re-sampling method (with a uniform sub-sample size, using the lowest 333 
number of sequences in each pair-wise comparison for the metacommunity (n = 8172), core (n = 6370), and 334 
satellite (n = 214) taxa groups).  Richness was significantly higher in the PMA treated metacommunity when 335 
compared to the non-treated metacommunity, confirmed using meta-analysis (Figure 6C).  When partitioned 336 
into groups, PMA treatment did not lead to a significant change in core group richness, but a significant 337 
change in richness was observed in the satellite group, again demonstrating that the majority of previously 338 
undetected taxa belonged to the satellite group, which drove the changes in diversity of the overall 339 
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metacommunity (Figure 6A&C).  Likewise, patterns similar to the observed changes in taxa richness were 340 
found for taxa composition, with overall significant changes in similarity in the PMA treated metacommunity 341 
(change of 0.23 ± 0.01) and the satellite group (0.63 ± 0.03). Conversely, the composition of the core group 342 
was not significantly affected by PMA treatment (0.03 ± 0.04) (Figure 6B&D). 343 
 344 
Impact of PMA treatment on the detection of recognised and emergent CF pathogens 345 
Analysis of the detection of recognised and emergent CF pathogens in the metacommunity indicated 346 
that P. aeruginosa, Stenotrophomonas maltophilia, and Streptococcus pneumoniae remained core group 347 
members regardless of PMA treatment. The most abundant taxon in the metacommunity, P. aeruginosa, was 348 
detected across the same 29 individual local communities regardless of prior treatment; accounting for 349 
76.1% (178952 of 235119) total sequence reads without PMA, and 77.1% (116444 of 151094) reads with 350 
PMA. However, the number of local communities in which S. maltophilia was detected increased from 10 (35 351 
reads) to 16 (112) with PMA. In contrast, the abundance and distribution of S. pneumoniae decreased from 352 
14 (408 reads) to 7 (36). Staphylococcus aureus (2 samples) and the candidate pathogen Streptococcus 353 
intermedius (part of the Streptococcus milleri group [3 samples]), both initially classified as satellite group 354 
members, were not detected with prior PMA treatment. Interestingly, four previously undetected taxa were 355 
detected in the metacommunity following PMA treatment. The recognised CF pathogens, Achromobacter 356 
xylosoxidans and Haemophilus influenzae were found to belong to the satellite group, being observed in 3 357 
and 1 local communities, respectively. Mycobacterium sp., some of which are regarded as pathogens in CF, 358 
was also found to belong to the satellite group, being detected in one local community. Conversely, 359 
members of the Burkholderia genus were found to belong to the core taxa group (7 samples and 83 reads) 360 
yet were undetected without prior PMA treatment (Supplementary Table S3). 361 
The distribution of taxa in the metacommunity that are associated with the oral cavity according to 362 
the Human Oral Microbiome Database (Dewhirst et al 2010) was also investigated. These taxa were found 363 
to be widely distributed across both the non-PMA and PMA treated metacommunity SADs (and therefore 364 
throughout both the core and satellite groups) (see Supplementary Table S3).  365 
 366 
Conclusions 367 
The lower respiratory system is a challenging environment for bacterial colonisation and persistence.  368 
Bacterial populations are subject to pressures from the host immune system and a wide variety of 369 
antimicrobial drugs.  Antibiotic treatment is the mainstay of CF therapy, particularly in response to acute 370 
14 
 
worsening of respiratory symptoms.  In order to assess the effectiveness of such interventions, it is essential 371 
that numbers of viable bacteria, and any reduction achieved as a result of therapy, can be accurately 372 
quantified. Our data indicate that DNA from non-viable bacteria and accumulated extracellular DNA make a 373 
significant contribution to estimations of bacterial abundance unless PMA treatment is employed.  As such, 374 
this suggests that the inclusion of a PMA treatment step is essential for accurate Q-PCR based enumeration. 375 
As CF bacterial communities are known to contain a wide phylogenetic range of species, all of which 376 
can be expected to be affected to different degrees by antimicrobial therapy and immune response, the 377 
populations of those species are likely to be present in differing relative viable and non-viable proportions.  378 
Determining the impact of non-viable cell exclusion (NVCE) treatment on community characteristics was 379 
therefore vital in the present study.  Our data clearly demonstrate that contribution of DNA from non-viable 380 
sources prevents the accurate characterisation of CF bacterial communities by pyrosequencing, and that 381 
NVCE approaches to limit this contribution is critical for community analysis.  382 
We demonstrate that suppressing the contribution of DNA from non-viable sources is essential for 383 
accurate characterisation of lower airway bacterial communities, in part because this method further 384 
identifies bacterial taxa that would otherwise go undetected. Important from a clinical perspective is the 385 
detection of known CF pathogens (both core and satellite group members) only with NVCE, increasing the 386 
sensitivity of molecular analyses for these pathogens, and providing vital information for prognosis and 387 
treatment.  Here we have used CF bacterial communities as a paradigm for lower respiratory infections in 388 
general.  Our findings suggest that a failure to implement a NVCE approach to analysing microbial 389 
communities may result in skewed results.  As this effect is due to the contribution of DNA from non-viable 390 
sources, such approaches are appropriate where communities are under antimicrobial stress, and where a 391 
characterisation of the viable bacterial community is sought. 392 
 393 
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Figure legends 530 
Fig. 1. The effect of PMA treatment on (A & B) total bacteria and (C & D) Pseudomonas aeruginosa 531 
abundance.  (A & C) Abundance (log10 scale CFU ml
-1
) measured by Q-PCR for paired samples that have 532 
been PMA treated (closed circles) and not treated (open circles).  Error bars represent the standard 533 
deviation of the mean (n = 3).  (B & D) Meta-analysis of abundance using Hedges’ d effect size measure 534 
between PMA treated and non-treated paired samples. Columns represent effect size and error bars 535 
represent the standard error (vi) of the effect size (n = 6).  Negative values indicate lower abundance in PMA 536 
treated samples.  Standard error bars that cross zero indicate no significant effect by PMA treatment. 537 
 538 
Fig. 2. The effect of PMA treatment on taxa richness and community similarity.  (A) Taxa richness for paired 539 
samples that have been PMA treated (closed circles) and not treated (open circles).  (C) Similarity (Sørensen 540 
index of similarity) of PMA treated (closed circles) samples compared to paired non-treated samples 541 
(assuming a similarity of 1 for comparison of a non-treated sample with itself).  Richness and similarity were 542 
calculated with a uniform re-sample size of 1637 sequences following 1000 iterations in each instance. Error 543 
bars represent the standard deviation of the mean (n = 1000).  Meta-analysis of (B) richness and (D) 544 
similarity using Hedges’ d effect size measure between PMA treated and non-treated paired samples. 545 
Columns represent effect size and error bars represent the standard error (vi) of the effect size (n = 2000).  546 
Standard error bars that cross zero indicate no significant effect by PMA treatment. 547 
 548 
Fig. 3. Overall meta-analysis for measures of abundance, diversity, and community similarity using Hedges’ 549 
d effect size measure between all PMA treated versus non-treated samples. Columns represent effect size 550 
and error bars represent the standard error (vi) of the effect size (n = 30). Standard error bars that cross zero 551 
indicate no significant effect by PMA treatment. 552 
 553 
Fig. 4. Distribution and dispersal of bacterial taxa across the (A & C) Non-PMA and (B & D) PMA treated 554 
metacommunity.  (A & B) The number of samples for which each bacterial taxon was observed, plotted 555 
against the mean abundance (log10 scale) across all 30 samples ([A] r
2
 = 0.86, F1,147 = 679.4, P < 0.0001; [B] 556 
r
2
 = 0.65, F1,231 = 425.7, P < 0.0001).  (C & D) Random and non-random dispersal through space visualised 557 
by decomposing the overall distribution using an index of dispersion based on the ratio of variance to the 558 
mean abundance for each bacterial taxon from the 30 samples.  The line depicts the 2.5 % confidence limit 559 
for the χ
2
 distribution.  The 97.5% confidence limit was not plotted, as no taxon fell below that line.  560 
19 
 
 561 
Fig. 5. Rank-abundance plots to determine patterns of taxa frequency for the (A) non-PMA and (B) PMA 562 
treated metacommunity. In each instance, the relative rank positions of core group (closed grey circles) and 563 
satellite group (open diamonds) taxa are given. Each plot has been fitted with a slope, and the slope values 564 
(b) are given, to determine changes in evenness: (A) r
2
 = 0.88, F1,147 = 1030.5, P < 0.0001; and (B) r
2
 = 0.88, 565 
F1,231 = 1669.1, P < 0.0001.  566 
 567 
Fig. 6. The effect of PMA treatment on metacommunity (A) richness and (B) community similarity 568 
(Sørensen).  In each instance, results are given for all taxa, the core and satellite groups.  Values and error 569 
bars (n = 1000) for richness and similarity were derived as described in the legends for Figs 1 & 2.  Also 570 
given are the meta-analysis of (C) richness and (D) similarity using Hedges’ d effect size measure.  Columns 571 
represent effect size and error bars represent the standard error (vi) of the effect size (n = 2000).  Standard 572 
error bars that cross zero indicate no significant effect by PMA treatment. 573 
 574 
Supplementary information 575 
Fig. S1. Rarefaction curves for paired non-PMA and PMA treated sputum samples. Number denotes sample 576 
number and P denotes PMA treatment. Standard error of mean represented by shaded area.  577 
 578 
Table S1 Quantitative PCR primer and probe sequences.  579 
 580 
Table S2 Bacterial diversity measure (S*, D, and H’) values estimated for paired non–PMA and PMA (P) 581 
sputum samples, and adjusted for uniform sample sizes (n) of 1637 sequence reads. Each value was 582 
estimated with a re-sample size of 1637 sequence reads and taking the mean from 1000 re-samplings. 583 
Given for each sample is: N, full sample size; S, observed species richness at full sample size; and 584 
estimates of species richness (S*), Simpson’s index of diversity (D), and Shannon-Wiener index of diversity 585 
(H’). Also given are confidence intervals for each of the three measures. 586 
 587 
Table S3 Bacterial taxa sampled across the 30 cystic fibrosis lung sputum samples.  Ae, denotes aerobe; 588 
An, Anerobe
1
; O, taxa associated with the oral microbiome
2
; P, recognised CF pathogen.  Also given for the 589 
non-PMA and PMA treated metacommunity are indications of core (C) and satellite (S) taxon group 590 
membership; lack of C or S designation indicates absence of detection of that taxon in the metacommunity. 591 
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Fig. S1. Rarefaction curves for paired non-PMA and PMA treated sputum samples. Number denotes 
sample number and P denotes PMA treatment. Standard error of mean represented by shaded area. 
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Table S1 Quantitative PCR primer and probe sequences. 
Primer Primer type Sequence (5' to 3') Reference 
EubF Total bacterial forward TCCTACGGGAGGCAGCAGT Nadkarni, 2002 
EubR Total bacterial reverse GGACTACCAGGGTATCTAATCCTGTT Nadkarni, 2002 
EubPR Total bacterial Taqman probe FAM-CGTATTACCGCGGCTGCTGGCAC-TAMRA Nadkarni, 2002 
PaerF P. aeruginosa forward TGCTGGTGGCACAGGACAT Shannon, 2007 
PaerR P. aeruginosa reverse TTGTTGGTGCAGTTCCTCATTG Shannon, 2007 
PaerPR P. aeruginosa Taqman probe FAM-CAGATGCTTTGCCTCAA-TAMRA Shannon, 2007 
 
 
All quantitative (Q)PCR analyses were performed in triplicate. Total bacterial density was 
determined using a Taqman assay, in which a 466 bp fragment of the 16S ribosomal RNA gene was 
amplified, as described previously (Nadkarni et al 2002). P. aeruginosa density was determined using 
a Taqman assay which amplified a 65 bp fragment of the regA gene, as described previously (Rogers 
et al 2010, Shannon et al 2007). Details of the relevant primers and probes used are shown in the 
Table above. Bacterial primers and probe were used at a concentration of 100 nM each, whereas P. 
aeruginosa-specific primers were used at a concentration of 1000 nM each, and the probe at a 
concentration of 250 nM. 1 μl (~800 ng) of mixed template DNA (human and microbial) was used in 
the P. aeruginosa assay. 1 μl of a 100 fold dilution (~8 ng) was used in the total bacterial assay. All 
PCR reactions were carried out in a total volume of 25 μl in Taqman® Universal PCR Mastermix 
(Applied Biosystems, Warrington, UK). Quantitative PCR assays were carried out using the 
Rotorgene 6000 (Qiagen,Crawley,UK) with a temperature profile of 50 °C for 2 min, 95 °C for 10 min, 
followed by 45 cycles at 95 °C for 15 s and 60 °C for 60 s. 
For both total bacterial and P. aeruginosa-specific quantitative PCR assays, densities (cfu/ml) 
were determined by comparison with standard curves generated from bacterial isolates. Nutrient broth 
cultures of P. aeruginosa (NCTC 12934/ ATCC 27853) were incubated at 37 °C for 16 h, with cfu ml−1 
estimated by incubation of dilutions (n = 4) on Columbia Blood Agar at 37° for 24 h, followed by 
colony counts. DNA was extracted from tenfold dilutions of these broth cultures in the same way as 
for the sputum samples, and RT-PCR was carried out as above on the DNA extracts. The standard 
curve generated using P. aeruginosa was used for both P. aeruginosa and total bacterial enumeration 
to allow direct comparisons to be made. 
 
Nadkarni MA, Martin FE, Jacques NA, Hunter N (2002). Determination of bacterial load by real-time PCR using a 
broad-range (universal) probe and primers set. Microbiology 148: 257-266. 
 
Shannon KE, Lee DY, Trevors JT, Beaudette LA (2007). Application of real-time quantitative PCR for the 
detection of selected bacterial pathogens during municipal wastewater treatment. Sci Total Environ 382: 121-
129. 
Table S2 Bacterial diversity measure (S*, D, and H’) values estimated for paired non–PMA and PMA 
(P) sputum samples, and adjusted for uniform sample sizes (n) of 1637 sequence reads.  Each value 
was estimated with a re-sample size of n = 1637 sequence reads and taking the mean from 1000 re-
samplings.  Given for each sample is: N, full sample size; S, observed species richness at full sample 
size; and estimates of species richness (S*), Simpson’s index of diversity (D), and Shannon-Wiener 
index of diversity (H’).  Also given are confidence intervals for each of the three measures. 
 
 
Name N S S* S*(2.5%) S*(97.5%) D D(2.5%) D(97.5%) H’ H’(2.5%) H’(97.5%)
1 24108 21 5 2.0 8.0 0.968 0.956 0.980 0.09 0.06 0.12 
1P 4448 70 39 32.0 45.0 0.601 0.568 0.631 1.06 0.97 1.15 
2 6728 15 6 3.0 9.0 0.967 0.953 0.979 0.10 0.06 0.13 
2P 4138 37 21 16.0 26.0 0.883 0.862 0.904 0.37 0.31 0.43 
3 22181 46 12 8.0 18.0 0.960 0.945 0.974 0.14 0.09 0.18 
3P 4570 49 26 20.0 31.0 0.878 0.855 0.900 0.40 0.34 0.48 
4 4860 54 37 32.0 42.0 0.389 0.362 0.416 1.61 1.54 1.70 
4P 3408 70 49 43.0 55.0 0.443 0.415 0.469 1.56 1.48 1.66 
5 5200 64 40 34.0 46.0 0.497 0.466 0.528 1.36 1.28 1.45 
5P 1979 34 30 27.0 33.0 0.341 0.315 0.367 1.78 1.70 1.86 
6 5359 52 34 29.0 39.0 0.414 0.388 0.442 1.51 1.43 1.59 
6P 1888 46 38 34.0 42.0 0.207 0.189 0.227 2.28 2.20 2.35 
7 6269 24 13 10.0 17.0 0.938 0.918 0.954 0.20 0.16 0.26 
7P 3656 20 9 6.0 14.0 0.984 0.974 0.992 0.06 0.03 0.10 
8 8260 20 11 7.0 14.0 0.945 0.926 0.960 0.18 0.13 0.23 
8P 6789 19 8 4.0 11.0 0.983 0.972 0.991 0.06 0.03 0.10 
9 5119 33 17 13.0 22.0 0.915 0.895 0.935 0.28 0.22 0.34 
9P 5755 17 7 3.0 11.0 0.989 0.981 0.996 0.04 0.02 0.07 
10 8797 15 7 5.0 10.0 0.964 0.951 0.976 0.11 0.08 0.15 
10P 14981 15 5 2.0 8.0 0.995 0.988 0.999 0.02 0.01 0.05 
11 7878 11 6 4.0 8.0 0.974 0.962 0.984 0.09 0.05 0.12 
11P 6967 47 21 16.0 26.0 0.918 0.898 0.936 0.28 0.22 0.34 
12 6379 12 8 5.0 10.0 0.954 0.939 0.968 0.14 0.10 0.18 
12P 5942 26 12 8.0 16.0 0.960 0.946 0.974 0.14 0.10 0.19 
13 6728 5 3 2.0 4.0 0.968 0.954 0.979 0.08 0.06 0.11 
13P 7616 10 4 2.0 7.0 0.985 0.976 0.993 0.05 0.02 0.08 
14 5147 28 14 10.0 19.0 0.937 0.919 0.953 0.21 0.15 0.26 
14P 5612 20 11 8.0 15.0 0.958 0.941 0.972 0.15 0.10 0.20 
15 7135 5 3 2.0 4.0 0.989 0.980 0.996 0.04 0.01 0.06 
15P 9007 20 7 4.0 10.0 0.979 0.968 0.988 0.07 0.04 0.11 
16 3714 5 3 2.0 5.0 0.965 0.952 0.978 0.09 0.06 0.12 
16P 9504 25 8 5.0 12.0 0.981 0.971 0.991 0.07 0.04 0.10 
17 26563 11 2 1.0 4.0 0.999 0.996 1.000 0.01 0.00 0.02 
17P 7416 19 8 5.0 12.0 0.974 0.962 0.984 0.09 0.06 0.13 
18 9909 21 5 3.0 9.0 0.970 0.958 0.981 0.09 0.06 0.12 
18P 4298 8 5 3.0 7.0 0.980 0.968 0.989 0.07 0.04 0.10 
19 7360 9 4 2.0 6.0 0.981 0.970 0.989 0.06 0.03 0.09 
19P 5915 25 13 9.0 17.0 0.949 0.932 0.963 0.18 0.13 0.23 
20 7020 4 2 2.0 4.0 0.981 0.971 0.989 0.05 0.03 0.08 
20P 4531 14 7 4.0 10.0 0.984 0.975 0.992 0.06 0.03 0.09 
21 2399 6 4 3.0 6.0 0.971 0.959 0.981 0.08 0.06 0.11 
21P 4635 8 5 3.0 7.0 0.985 0.976 0.993 0.05 0.03 0.08 
22 12488 51 38 34.0 42.0 0.119 0.111 0.128 2.57 2.52 2.63 
22P 2191 41 35 31.0 38.0 0.145 0.137 0.153 2.34 2.28 2.40 
23 9897 45 34 30.0 38.0 0.111 0.105 0.118 2.52 2.46 2.58 
23P 3692 44 36 32.0 40.0 0.151 0.140 0.163 2.39 2.33 2.46 
Table S2 (continued) 
Name N S S* S*(2.5%) S*(97.5%) D D(2.5%) D(97.5%) H H(2.5%) H(97.5%) 
24 6362 44 34 30.0 37.0 0.108 0.101 0.116 2.59 2.53 2.64 
24P 3468 41 34 31.0 38.0 0.125 0.117 0.132 2.46 2.40 2.52 
25 2721 44 35 31.0 39.0 0.144 0.135 0.156 2.46 2.39 2.51 
25P 7787 50 38 35.0 42.0 0.083 0.077 0.089 2.87 2.81 2.91 
26 2783 44 37 34.0 41.0 0.140 0.129 0.151 2.50 2.44 2.57 
26P 2625 57 49 44.0 52.0 0.128 0.117 0.139 2.68 2.61 2.75 
27 5539 48 34 30.0 38.0 0.176 0.163 0.190 2.27 2.20 2.33 
27P 1637 16 15 13.0 16.0 0.178 0.171 0.187 1.93 1.88 1.97 
28 4569 52 39 35.0 43.0 0.107 0.101 0.114 2.61 2.56 2.67 
28P 1865 18 16 13.0 18.0 0.304 0.286 0.323 1.56 1.51 1.61 
29 1663 41 37 34.0 40.0 0.099 0.093 0.105 2.63 2.57 2.68 
29P 2121 42 37 33.0 40.0 0.194 0.181 0.208 2.21 2.14 2.27 
30 1984 45 39 36.0 43.0 0.100 0.095 0.107 2.63 2.57 2.69 
30P 2653 47 41 36.0 44.0 0.166 0.154 0.179 2.43 2.36 2.50 
 
 
 
Table S3 Bacterial taxa sampled across the 30 cystic fibrosis lung sputum samples.  Ae, denotes 
aerobe; An, Anerobe1; O, taxa associated with the oral microbiome2; P, recognised CF pathogen.  
Also given for the non-PMA and PMA treated metacommunity are indications of core (C) and satellite 
(S) taxon group membership; lack of C or S designation indicates absence of detection of that taxon 
in the metacommunity. 
 
Class Family Taxon name Code Non-PMA PMA 
Acidobacteria Acidobacteriaceae Acidobacterium sp Ae S S 
Actinobacteria Actinomycetaceae Actinomyces meyeri Ae, O S S 
Actinomyces odontolyticus Ae, O C  C  
Actinomyces sp Ae, O C  C  
Corynebacteriaceae Corynebacterium durum Ae, O S 
Corynebacterium jeikeium Ae S 
C. pseudodiphtheriticum Ae, O S 
Corynebacterium segmentosum Ae S S 
Corynebacterium sp Ae, O S C 
Geodermatophilaceae Geodermatophilus sp Ae S 
Gordoniaceae Gordonia rubripertincta Ae S S 
Intrasporangiaceae Janibacter sp Ae S 
Microbacteriaceae Microbacterium lacticum Ae S 
Micrococcaceae Arthrobacter psychrolactophilus Ae S 
Arthrobacter sp Ae C 
Citricoccus sp Ae S 
Kocuria sp Ae, O S S 
Micrococcus sp Ae C  S 
Rothia dentocariosa Ae, O C  C 
Rothia mucilaginosa Ae, O C  C 
Rothia sp Ae, O C  C 
Mycobacteriaceae Mycobacterium sp Ae S 
Nocardioidaceae Nocardioides alkalitolerans Ae S 
Propionibacteriaceae Propionibacterium acnes Ae S C 
Propionibacterium avidum Ae, O S 
Propionibacterium propionicum Ae, O C  S 
Propionibacterium sp Ae, O S C 
Sporichthyaceae Sporichthya polymorpha Ae S 
Bifidobacteriaceae Scardovia sp An, O S 
Coriobacteriaceae Atopobium parvulum An, O S S 
Eggerthella sp An, O S 
Bacteroidia Bacteroidaceae Bacteroides acidifaciens An S 
Bacteroides ovatus An S 
Bacteroides salyersiae An S 
Bacteroides sp An C 
Bacteroides thetaiotaomicron An S 
Porphyromonadaceae Parabacteroides distasonis An S 
Porphyromonas bennonis An C  
Porphyromonas catoniae An, O S S 
Porphyromonas sp An C  C 
Prevotellaceae Prevotella copri An S 
Prevotella denticola An, O C  C 
Prevotella histicola An, O C  S 
Prevotella melaninogenica An, O C  C 
Prevotella nanceiensis An C  C 
Prevotella oris An, O S S 
Prevotella oulorum An, O C  S 
Table S3 (Continued) 
Class Family Taxon name Code Non-PMA PMA 
Prevotella pallens An, O C  C 
Prevotella ruminicola An S 
Prevotella salivae An, O C  C 
Prevotella sp An, O C  C 
Prevotella veroralis An, O C  S 
Bacteroidia Bacteroidales bacterium An S 
Cytophagia Cytophagaceae Flexibacter sp Ae S 
Flavobacteria Flavobacteriaceae Bergeyella zoohelcum Ae, O C  S 
Capnocytophaga gingivalis Ae, O C  C 
Capnocytophaga granulosa Ae, O S 
Capnocytophaga sp Ae, O C  C 
Chryseobacterium sp Ae S 
Maribacter sp Ae S 
Sphingobacteria Chitinophagaceae Flavisolibacter sp Ae S 
Sphingobacteriaceae Mucilaginibacter sp Ae S 
Pedobacter duraquae Ae S 
Caldilineae Caldilineaceae Caldilinea sp An S 
Cyanobacteria Chroococcaceae Gloeocapsa sp Ae S 
Nostocaceae Anabaena augstumalis Ae S 
Anabaena cylindrica Ae S 
Nostoc commune Ae S 
Scytonemataceae Brasilonema terrestre Ae S 
Scytonema sp Ae S 
Stigonemataceae Symphyonemopsis sp Ae S 
Elusimicrobia Elusimicrobiaceae Elusimicrobium sp An S 
Bacilli Bacillaceae Anoxybacillus flavithermus Ae S 
Bacillus cereus Ae C 
Bacillus licheniformis Ae S 
Bacillus sp Ae S C 
Gemella haemolysans Ae, O C  C 
Gemella sanguinis Ae, O C  C 
Gemella sp Ae, O C  S 
Paenibacillaceae Paenibacillus sp Ae, O S C 
Planococcaceae Planococcus sp Ae S 
Staphylococcaceae Staphylococcus aureus Ae, P S 
Staphylococcus auricularis Ae S 
Staphylococcus epidermidis Ae, O S C 
Staphylococcus haemolyticus Ae S S 
Staphylococcus sp Ae C 
Staphylococcus warneri Ae, O S 
Aerococcaceae Abiotrophia defectiva Ae, O S 
Abiotrophia sp Ae, O C  C 
Facklamia sp Ae S 
Carnobacteriaceae Dolosigranulum sp Ae, O S 
Granulicatella adiacens Ae, O C  C 
Granulicatella elegans Ae, O S S 
Granulicatella sp Ae, O C  C 
Enterococcaceae Enterococcus sp Ae S 
Lactobacillaceae Lactobacillus delbrueckii Ae S 
Lactobacillus mucosae Ae S 
Lactobacillus rhamnosus Ae, O S S 
Lactobacillus sp Ae, O S C 
Table S3 (Continued) 
Class Family Taxon name Code Non-PMA PMA 
Streptococcaceae Streptococcus australis Ae C  C 
Streptococcus cristatus Ae C  C 
Streptococcus infantis Ae, O C  C 
Streptococcus intermedius Ae, O S 
Streptococcus mitis Ae, O C  C 
Streptococcus mutans Ae, O S 
Streptococcus oralis Ae, O S S 
Streptococcus parasanguinis Ae, O C  C 
Streptococcus pneumoniae Ae, O,P C  C 
Streptococcus salivarius Ae, O C  C 
Streptococcus sanguinis Ae, O C  C 
Streptococcus sp Ae, O C  C 
Streptococcus thermophilus Ae, O S S 
Streptococcus vestibularis Ae, O C  C 
Clostridia Clostridiaceae Anaerococcus sp An, O S S 
Blautia hansenii An S 
Blautia sp An S 
Clostridium neopropionicum An S 
Clostridium orbiscindens An S 
Clostridium sp An C 
Finegoldia sp An, O C  S 
Mogibacterium vescum An, O S 
Peptoniphilus sp An, O S C 
Tissierella sp An S 
Eubacteriaceae Eubacterium eligens An S 
Eubacterium saburreum An, O S C 
Eubacterium sp An S 
Lachnospiraceae Anaerostipes sp An C  S 
Catonella sp An, O S 
Dorea sp An, O S 
Lachnospira pectinoschiza An S S 
Oribacterium sinus An, O S S 
Oribacterium sp An, O S 
Roseburia intestinalis An S 
Roseburia inulinivorans An S 
Oscillospiraceae Oscillibacter valericigenes An S S 
Peptostreptococcaceae Peptostreptococcus sp An S 
Ruminococcaceae Faecalibacterium prausnitzii Ae S S 
Faecalibacterium sp Ae S 
Oscillospira guilliermondii An S 
Ruminococcus obeum An C 
Veillonellaceae Dialister sp An, O S 
Megamonas sp An S 
Megasphaera micronuciformis An, O S S 
Selenomonas dianae An, O C  S 
Selenomonas sp An, O S S 
Selenomonas sputigena An, O C  C 
Veillonella atypica An, O C  C 
Veillonella dispar An, O C  C 
Veillonella parvula An, O C  C 
Veillonella sp An, O S 
Thermoanaerobacteraceae Gelria sp An S 
Table S3 (Continued) 
Class Family Taxon name Code Non-PMA PMA 
Thermoanaerobacter sp An S 
Erysipelotrichi Erysipelotrichaceae Bulleidia sp An, O S 
Catenibacterium sp An C  S 
Solobacterium moorei An, O S 
Solobacterium sp An, O S 
Turicibacter sanguinis An S 
Fusobacteria Fusobacteriaceae Fusobacterium nucleatum An, O S 
Fusobacterium periodonticum An, O S 
Fusobacterium sp An, O C  S 
Leptotrichia sp An, O S S 
Leptotrichia wadei An, O S 
Gemmatimonadetes Gemmatimonadaceae Gemmatimonas sp Ae S 
Lentisphaerae Victivallaceae Victivallis sp An S 
Nitrospira Nitrospiraceae Nitrospira sp Ae S 
Alphaproteobacteria Caulobacteraceae Brevundimonas diminuta Ae, O S 
Brevundimonas sp Ae C  S 
Caulobacter sp Ae, O S 
Bradyrhizobiaceae Bradyrhizobium sp Ae, O C 
Hyphomicrobiaceae Devosia sp Ae S 
Hyphomicrobium sp Ae S 
Methylobacteriaceae Methylobacterium sp Ae C  
Methylobacterium zatmanii Ae S 
Rhizobiaceae Rhizobium sp Ae S 
Rhodobacteraceae Pannonibacter phragmitetus Ae S 
Paracoccus sp Ae S S 
Rhodobacter sp Ae S S 
Roseobacter sp Ae C 
Acetobacteraceae Roseomonas gilardii Ae S 
Rhodospirillaceae Azospirillum sp Ae S 
Defluviicoccus sp Ae S 
Thalassospira sp Ae S 
Anaplasmataceae Wolbachia sp Ae S 
Sphingomonadaceae Novosphingobium sp Ae S 
Sphingomonas sp Ae S S 
Betaproteobacteria Alcaligenaceae Achromobacter sp Ae S 
Achromobacter xylosoxidans Ae, P S 
Alcaligenes faecalis Ae S 
Alcaligenes sp Ae C 
Sutterella sp Ae S 
Burkholderiaceae Burkholderia sp Ae, P C 
Lautropia mirabilis Ae, O C  C 
Lautropia sp Ae, O C  S 
Ralstonia sp Ae, O C  C 
Mitsuaria sp Ae S 
Comamonadaceae Acidovorax defluvii Ae S 
Acidovorax sp Ae S 
Comamonas sp Ae S 
Diaphorobacter sp Ae S 
Pelomonas sp Ae S 
Ramlibacter sp Ae S 
Oxalobacteraceae Duganella sp Ae S 
Table S3 (Continued) 
Class Family Taxon name Code Non-PMA PMA 
Herbaspirillum sp Ae S S 
Janthinobacterium sp Ae S 
Massilia sp Ae C  C 
Massilia timonae Ae S S 
Neisseriaceae Eikenella corrodens Ae, O S 
Kingella denitrificans Ae, O S S 
Kingella oralis Ae, O S S 
Kingella sp Ae, O C  S 
Neisseria bacilliformis Ae, O C  S 
Neisseria mucosa Ae, O S S 
Neisseria sp Ae, O S S 
Rhodocyclaceae Sterolibacterium sp Ae S 
Zoogloea oryzae Ae S 
Deltaproteobacteria Desulfobulbaceae Desulfofustis sp Ae S 
Epsilonproteobacteria Campylobacteraceae Campylobacter concisus Ae, O S S 
Campylobacter curvus Ae, O S S 
Campylobacter gracilis Ae, O C  S 
Campylobacter sp Ae, O C  
Gammaproteobacteria Aeromonadaceae Aeromonas sp Ae S S 
Enterobacteriaceae Citrobacter sp Ae S 
Enterobacter hormaechei Ae, O S 
Enterobacter sp Ae, O S C 
Escherichia coli Ae, O C 
Escherichia sp Ae, O S C 
Klebsiella sp Ae S C 
Pantoea sp Ae S 
Pectobacterium carotovorum Ae S 
Proteus mirabilis Ae, O S 
Proteus sp Ae, O S 
Salmonella enterica Ae S 
Serratia sp Ae S 
Shigella flexneri Ae S 
Shigella sp Ae C 
Alcanivoracaceae Alcanivorax dieselolei Ae S 
Pasteurellaceae Actinobacillus pleuropneumoniae Ae C  S 
Actinobacillus sp Ae S 
Aggregatibacter aphrophilus Ae, O S 
Aggregatibacter sp Ae, O S 
Haemophilus influenzae Ae, P S 
Haemophilus parahaemolyticus Ae, O C  S 
Haemophilus sp Ae, O C  C 
Pasteurella skyensis Ae S 
Terrahaemophilus aromaticivorans An, O C  S 
Moraxellaceae Acinetobacter radioresistens Ae S C 
Acinetobacter sp Ae S C 
Psychrobacter fulvigenes Ae S 
Psychrobacter sp Ae S 
Pseudomonadaceae Pseudomonas aeruginosa Ae, P C  C 
Pseudomonas delhiensis Ae S S 
Pseudomonas fluorescens Ae, O C  C 
Table S3 (Continued) 
Class Family Taxon name Code Non-PMA PMA 
Pseudomonas pertucinogena Ae S 
Pseudomonas pseudoalcaligenes Ae, O C  C 
Pseudomonas putida Ae C  S 
Pseudomonas tropicalis Ae S 
Vibrionaceae Vibrio harveyi Ae S 
Vibrio sp Ae S S 
Xanthomonadaceae Lysobacter panaciterrae Ae S 
Pseudoxanthomonas suwonensis Ae S S 
Stenotrophomonas maltophilia Ae, P C  C 
Stenotrophomonas sp Ae C  C 
Xanthomonas sp Ae, O C  C 
Mollicutes Mollicutes(family) Mollicutes sp An S 
Mycoplasmataceae Ureaplasma urealyticum Ae S 
TM7(class) TM7(family) TM7 uncultured Ae, O C  C 
Verrucomicrobiae Verrucomicrobiaceae Akkermansia muciniphila An S 
 
1 Only strict anaerobes were classified as anaerobes, whereas aerobes, facultative anaerobes, and 
microaerophiles were classified as aerobes, as described previously (van der Gast et al., 2011). 
 
2 Classification of oral taxa was according to the Human Oral Microbiome Database (Dewhirst et al., 
2010). 
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